Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions
Cannabis Dependence
Interventions
DRUG

N-Acetylcysteine

Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.

DRUG

Placebo

Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.

Trial Locations (6)

29671

Behavioral Health Services of Pickens County, Pickens

40502

University of Kentucky, Lexington

78229

University of Texas Health Science Center at San Antonio, San Antonio

90025

UCLA Integrated Substance Abuse Programs, Los Angeles

97214

CODA, Inc., Portland

06511

APT Foundation, Inc., New Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Medical University of South Carolina

OTHER

NCT01675661 - Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment | Biotech Hunter | Biotech Hunter